Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : ASK Vendit Off Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: DOUG H who wrote (7475)	2/5/2000 6:11:00 AM
From: Vendit™	Read Replies (2) \| Respond to of 19374

Looks like CORR is also on a recently recommended Health Care Services & Supplies Industry buy list. Message 12774994 The chart is not too shabbie either. The fact that it closed near it's daily high is indicative that the momentum will spill over into Monday. askresearch.com

To: DOUG H who wrote (7475)	2/5/2000 6:31:00 AM
From: nohalo	Read Replies (2) \| Respond to of 19374

CORR- Doug, thank you for the superb review by your friend, who is obviously very knowledgable. I have been doing some research as well, and I agree with his views. I will hopefully post this, but my wife has "found" some time in our schedule next week, and is planning a short vacation. I think we're flying off to some unknown, warm destination tomorrow. I feel that more head to head studies will be done vis-a-vis ReoPro and Integrelin. As well, I think the indication to use such agents only for stents is too narrow, and CORR and its partner Schering-Plough will probably be looking for indications to compete with Genentech's TPA drug(a big blockbuster).And I'm sure you know what happened to genentech after its discovery- it went to the moon, and spawned the Biotech mania. Your friend mentions that "the market for these products will be expanding rapidly for economic reasons" This is an understatement, if I can call it that. This development means that coronary stents with GPIIb/IIIa receptors will be the Standard of Care, as well as the least expensive option for around a million or more cases per year, with minimal hospitalization. The HMOs and medicare will be falling all over this option. Factor in the fact that America's population is aging rapidly, and that Coronary Artery Disease is the commonest cause of hospital admissions in the elderly, and you can begin to see the scope of CORR's study results and the reason for our enthusiasm. Add to this the TA endorsement by Reid, and we have the makings of at least a three bagger, over the medium term. I do not think that the market has woken up to these facts yet, and hopefully this will take a few weeks, so that we can accumulate. Beware, though. This is not a daytrader's arena. Too complex, I think, and not enough analysts have said anything yet. Finally, thank you for making me post my longest post ever! Best wishes, DA